Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care

EMUC 2024

Published: 17 Dec 2024

Views: 625

Rating:

Save

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Prof Jens Bedke speaks to ecancer about the results of the SUNNIFORECAST trial.

This study investigates the effectiveness of ipilimumab and nivolumab as a first-line treatment for metastatic non-clear cell renal cell carcinoma, comparing it to standard TKI monotherapy.

The trial achieved an impressive overall survival rate of over 86% after 12 months despite challenges in progression-free survival.

Specific patient subgroups, especially PD-1-positive individuals, showed notable benefits, highlighting the need for tailored treatment approaches.

Related Videos

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

More from ecancer